These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 31399272)
21. Adapting and scaling a single site DEA X-waiver training program to a statewide initiative: Implementing GetWaiveredTX. Potter JS; Finley EP; King VL; Lanham HJ; Schmidt S; Schneegans S; Rosen KD J Subst Abuse Treat; 2022 Jun; 137():108688. PubMed ID: 35058105 [TBL] [Abstract][Full Text] [Related]
22. Experiences of three states implementing the Medicaid health home model to address opioid use disorder-Case studies in Maryland, Rhode Island, and Vermont. Clemans-Cope L; Wishner JB; Allen EH; Lallemand N; Epstein M; Spillman BC J Subst Abuse Treat; 2017 Dec; 83():27-35. PubMed ID: 29129193 [TBL] [Abstract][Full Text] [Related]
23. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers. LaBelle CT; Han SC; Bergeron A; Samet JH J Subst Abuse Treat; 2016 Jan; 60():6-13. PubMed ID: 26233698 [TBL] [Abstract][Full Text] [Related]
24. Buprenorphine prescribing practice trends and attitudes among New York providers. Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694 [TBL] [Abstract][Full Text] [Related]
25. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018. Ghertner R Drug Alcohol Depend; 2019 Nov; 204():107527. PubMed ID: 31525570 [TBL] [Abstract][Full Text] [Related]
27. Impact of Policy Change on Access to Medication for Opioid Use Disorder in Primary Care. Krupp J; Hung F; LaChapelle T; Yarrington ME; Link K; Choi Y; Chen H; Marais AD; Sachdeva N; Chakraborty H; McKellar MS South Med J; 2023 Apr; 116(4):333-340. PubMed ID: 37011580 [TBL] [Abstract][Full Text] [Related]
28. Barriers and perceived usefulness of an ECHO intervention for office-based buprenorphine treatment for opioid use disorder in North Carolina: A qualitative study. Shea CM; Gertner AK; Green SL Subst Abus; 2021; 42(1):54-64. PubMed ID: 31809679 [TBL] [Abstract][Full Text] [Related]
29. Advanced Practice Provider-Led Medication for Opioid Use Disorder Programs for Pregnant and Parenting Women. Pressley Byrd D; Galvin S; Ramage M; Johnson E J Midwifery Womens Health; 2022 May; 67(3):384-393. PubMed ID: 35522126 [TBL] [Abstract][Full Text] [Related]
30. Full agonist opioid prescribing by primary care clinicians after buprenorphine training. Gadomski A; Anderson J; Chung YK; Krupa N; Jenkins P Subst Abus; 2022; 43(1):69-75. PubMed ID: 32150525 [TBL] [Abstract][Full Text] [Related]
31. County-level access to opioid use disorder medications in medicare Part D (2010-2015). Abraham AJ; Adams GB; Bradford AC; Bradford WD Health Serv Res; 2019 Apr; 54(2):390-398. PubMed ID: 30665272 [TBL] [Abstract][Full Text] [Related]
32. Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA; Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068 [TBL] [Abstract][Full Text] [Related]
33. Deploying science to change hearts and minds: Responding to the opioid crisis. Walsh SL; Long KQX Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116 [TBL] [Abstract][Full Text] [Related]
34. Rationale, evidence, and steps for implementation of medication for opioid use disorder treatment programs in HIV primary care settings. Brizzi M; Green SB AIDS Care; 2023 Nov; 35(11):1760-1767. PubMed ID: 37039558 [TBL] [Abstract][Full Text] [Related]
35. The payer's role in addressing the opioid epidemic: It's more than money. Molfenter T; McCarty D; Jacobson N; Kim JS; Starr S; Zehner M J Subst Abuse Treat; 2019 Jun; 101():72-78. PubMed ID: 31174716 [TBL] [Abstract][Full Text] [Related]
36. Collaborative health systems ECHO: The use of a tele-education platform to facilitate communication and collaboration with recipients of state targeted response funds in Pennsylvania. Kawasaki S; Hwang G; Buckner K; Francis E; Huffnagle S; Kraschnewski J; Vulgamore P; Lucas A; Barbour J; Crawford M; Thomas L; Fuller M; Meyers J; Swartzentruber G; Levine R Subst Abus; 2022; 43(1):892-900. PubMed ID: 35192446 [No Abstract] [Full Text] [Related]
37. The Comprehensive Addiction and Recovery Act: Opioid Use Disorder and Midwifery Practice. Murphy J; Goodman D; Johnson MC; Terplan M Obstet Gynecol; 2018 Mar; 131(3):542-544. PubMed ID: 29420414 [TBL] [Abstract][Full Text] [Related]
38. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Jones CM; McCance-Katz EF Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876 [TBL] [Abstract][Full Text] [Related]
39. Increasing Access to Buprenorphine in Safety-Net Primary Care Clinics: The New York City Buprenorphine Nurse Care Manager Initiative. Kaplan-Dobbs M; Kattan JA; Tuazon E; Jimenez C; Saleh S; Kunins HV Am J Public Health; 2021 Feb; 111(2):215-218. PubMed ID: 33351661 [TBL] [Abstract][Full Text] [Related]